Skip to main content
Journal cover image

Multiple hour antifibrotic drug release enabled by a thermosensitive quadpolymer.

Publication ,  Journal Article
Jayes, FL; Corder, RD; Vachieri, RB; Khan, SA; Taylor, DK
Published in: Int J Pharm
January 25, 2025

Injectable drug delivery for uterine fibroid therapy is an ambitious, possibly fertility-preserving concept, that could meet the challenges associated with the structure of these tumors and their location in the uterus. This study was conducted to advance a thermosensitive injectable quadpolymer for effective sustained release of anti-fibrotic drug formulations and to evaluate the feasibility of its use for delivery of the anti-fibrotic drug pirfenidone as a therapy to reduce fibroid cell proliferation. A series of quadpolymers were prepared by free radical polymerization of N-isopropylacrylamide (NIPAM) with different amounts of polylactic acid functionalized hydroxyethyl methacrylate (HEMA-PLA), acrylic acid (AAc), and methacrylate functionalized hyperbranched polyglycerol (HPG-MA) to optimize the sol-gel phase transition temperature and mechanical stiffness. Poly(NIPAM-co-HEMA-PLA-co-AAc-co-HPG-MA) with feed ratio (83-7-1-9), at 17% w/v, readily formed an aqueous solution that could be manipulated by syringe at room temperature. The quadpolymer also rapidly formed a stable gel at physiological body temperature, and partially biodegraded over time as confirmed by several spectroscopic characterization techniques. To evaluate the potential range of utility, quadpolymer 83-7-1-9 was loaded in-vitro with caffeine (a prototype hydrophilic drug) or the hydrophobic drug pirfenidone. Pirfenidone-loaded quadpolymer 83-7-1-9 formulations released 50% of drug loaded in double the time as compared to other reported liposome and nanoparticle injectable pirfenidone formulations. Furthermore, treatment of cultured fibroid cells with pirfenidone-loaded quadpolymer 83-7-1-9 formulations confirmed that activity of pirfenidone was preserved and proliferation of fibroid cells was inhibited. These results support that quadpolymer 83-7-1-9 is a promising candidate to be further developed for localized delivery of drugs for uterine fibroid therapy.

Duke Scholars

Published In

Int J Pharm

DOI

EISSN

1873-3476

Publication Date

January 25, 2025

Volume

669

Start / End Page

125097

Location

Netherlands

Related Subject Headings

  • Uterine Neoplasms
  • Temperature
  • Pyridones
  • Polymers
  • Polyesters
  • Pharmacology & Pharmacy
  • Methacrylates
  • Leiomyoma
  • Humans
  • Glycerol
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jayes, F. L., Corder, R. D., Vachieri, R. B., Khan, S. A., & Taylor, D. K. (2025). Multiple hour antifibrotic drug release enabled by a thermosensitive quadpolymer. Int J Pharm, 669, 125097. https://doi.org/10.1016/j.ijpharm.2024.125097
Jayes, Friederike L., Ria D. Corder, Robert B. Vachieri, Saad A. Khan, and Darlene K. Taylor. “Multiple hour antifibrotic drug release enabled by a thermosensitive quadpolymer.Int J Pharm 669 (January 25, 2025): 125097. https://doi.org/10.1016/j.ijpharm.2024.125097.
Jayes FL, Corder RD, Vachieri RB, Khan SA, Taylor DK. Multiple hour antifibrotic drug release enabled by a thermosensitive quadpolymer. Int J Pharm. 2025 Jan 25;669:125097.
Jayes, Friederike L., et al. “Multiple hour antifibrotic drug release enabled by a thermosensitive quadpolymer.Int J Pharm, vol. 669, Jan. 2025, p. 125097. Pubmed, doi:10.1016/j.ijpharm.2024.125097.
Jayes FL, Corder RD, Vachieri RB, Khan SA, Taylor DK. Multiple hour antifibrotic drug release enabled by a thermosensitive quadpolymer. Int J Pharm. 2025 Jan 25;669:125097.
Journal cover image

Published In

Int J Pharm

DOI

EISSN

1873-3476

Publication Date

January 25, 2025

Volume

669

Start / End Page

125097

Location

Netherlands

Related Subject Headings

  • Uterine Neoplasms
  • Temperature
  • Pyridones
  • Polymers
  • Polyesters
  • Pharmacology & Pharmacy
  • Methacrylates
  • Leiomyoma
  • Humans
  • Glycerol